One study has identified that, increased serum levels of cTnT (cardiac injury biomarker) and N-terminal pro-brain natriuretic peptide (NT-proBNP; cardiomyopathy biomarker), followed by treatment with doxorubicin, may act as biomarkers for cardiac injury and cardiomyopathy in children with high-risk ALL (52 T-ALL and 434 B-ALL) (164). The gene discussed is TNNT2; the disease is acute lymphoblastic leukemia.